EUVIMEDEUVIMED entdecken
Übersichtsarbeit

What Every Vascular Surgeon Should Know About Vascular Ehlers-Danlos Syndrome

Tiffany Lian, Apoorva Bhandari, Sherene Shalhub

Annals of Vascular Surgery · 2026-08 · 129 · 302-306

DOI: 10.1016/j.avsg.2026.03.032 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Annals of Vascular Surgery, 2026-08. Verfasst von Tiffany Lian und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Vascular and Endovascular Surgery, Department of Surgery, Oregon Health & Science University, Portland, OR. Hauptthemen laut MEDLINE: Ehlers-Danlos Syndrome, Type IV, Endovascular Procedures, Vascular Surgical Procedures. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vascular Ehlers-Danlos syndrome (VEDS) vascular type is a rare autosomal dominant disorder caused by pathogenic variants in the COL3A1, resulting in abnormal type III collagen and a high risk of arterial dissection, rupture, and other life-threatening complications at a young age. Diagnosis requires a high index of clinical suspicion and confirmatory genetic testing, which also enables cascade screening and informs prognosis through genotype-phenotype correlations. Management is centered on multidisciplinary care, including vascular surgery, cardiology, and genetics, with baseline head-to-pelvis vascular imaging followed by annual to biannual surveillance. Medical therapy emphasizes strict blood pressure control, typically with beta-blockers and angiotensin receptor blockers, alongside lifestyle modification and avoidance of high-risk medications. Although historically associated with high morbidity, both open and endovascular interventions are increasingly feasible with careful patient selection and meticulous technique, though risks of iatrogenic injury and device-related complications remain substantial. Longitudinal care requires ongoing surveillance and psychosocial support, and pregnancy carries significant maternal risk necessitating specialized management. Advances in genetic characterization and operative strategies have improved outcomes; however, substantial morbidity persists, and future efforts are focused on integrating biologic and ultrastructural markers of tissue integrity to refine risk stratification and enable personalized decision making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ehlers-Danlos Syndrome, Type IVEndovascular ProceduresVascular Surgical ProceduresFemaleHumansCollagen Type IIIDissection, Blood VesselGenetic Predisposition to DiseaseGenetic TestingPatient Care TeamPhenotypePredictive Value of TestsRisk AssessmentRisk FactorsTreatment Outcome

Substanzen

COL3A1 protein, humanCollagen Type III

Autor:innen und Institutionen

  • Division of Vascular and Endovascular Surgery, Department of Surgery, Oregon Health & Science University, Portland, OR.
  • Division of Vascular and Endovascular Surgery, Department of Surgery, Oregon Health & Science University, Portland, OR; Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, OR. Ele…

Zitieren

APA

Lian, T., Bhandari, A., & Shalhub, S. (2026). What Every Vascular Surgeon Should Know About Vascular Ehlers-Danlos Syndrome. Annals of Vascular Surgery, 129, 302-306. https://doi.org/10.1016/j.avsg.2026.03.032

Vancouver

Lian T, Bhandari A, Shalhub S. What Every Vascular Surgeon Should Know About Vascular Ehlers-Danlos Syndrome. Annals of Vascular Surgery. 2026;129:302-306. doi:10.1016/j.avsg.2026.03.032

BibTeX
@article{Lian2026,
  author = {Lian, Tiffany and Bhandari, Apoorva and Shalhub, Sherene},
  title = {What Every Vascular Surgeon Should Know About Vascular Ehlers-Danlos Syndrome},
  journal = {Annals of Vascular Surgery},
  year = {2026},
  volume = {129},
  pages = {302--306},
  doi = {10.1016/j.avsg.2026.03.032}
}
Kostenlos starten →